MedTrace Logo

the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer

NCT06378840 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-04-23

No results posted yet for this study

Summary

To explore the predictive value of immune cells by single-cell sequencing on the outcome of locally advanced cervical cancer treated by concurrent chemoradiotherapy Followed by PD-1 inhibitor

Conditions

  • Locally Advanced Cervical Carcinoma
  • Concurrent Chemoradiotherapy
  • Immunotherapy

Interventions

RADIATION

Nab-paclitaxel/Platinum, Sintilimab

Sintilimab Combined With Concurrent Nab-paclitaxel/Platinum-based Chemoradiotherapy

Sponsors & Collaborators

  • RenJi Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-12-30
Completion
2024-12-30
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06378840 on ClinicalTrials.gov